要闻！iPadOS 18 细节功能发布：原生计算器登场，悬浮栏再升级

iPadOS 18 细节功能发布：原生计算器登场，悬浮栏再升级

北京，2024年6月14日 - 苹果在WWDC24开发者大会上正式发布了iPadOS 18操作系统，为iPad用户带来了诸多新功能和细节改进。其中，最受瞩目的莫过于原生计算器的加入以及悬浮栏的升级。

原生计算器的加入，终于满足了iPad用户多年的期待。该计算器支持多种计算模式，包括基本运算、科学计算、绘图计算等，并支持手写输入，方便用户进行复杂公式的求解和图表绘制。此外，计算器还提供了单位换算功能，方便用户进行不同单位之间的转换。

悬浮栏在iPadOS 18中也得到了进一步增强。现在，用户可以将多个应用程序的悬浮栏组合在一起，并自由调整它们的尺寸和位置。这使得用户能够更方便地同时处理多个任务，提高工作效率。

以下是一些iPadOS 18的其他新功能和细节改进：

• 支持在“备忘录”中使用Math Notes进行数学计算
• 支持自定义主屏幕和控制中心
• 照片应用新增每日精选内容和照片集置顶功能
• 信息应用支持定时发送信息和新增多种文字格式
• Safari浏览器支持利用机器学习呈现网页中的关键信息

总体而言，iPadOS 18是一次功能完善且细节丰富的更新，为iPad用户带来了更加便捷和高效的使用体验。

以下是本次更新的一些亮点：

• 原生计算器的加入，满足了用户多年期待
• 悬浮栏功能进一步增强，提高工作效率
• 支持自定义主屏幕和控制中心，个性化十足
• 照片应用新增多种功能，方便用户管理和欣赏照片
• 信息应用新增功能，丰富沟通体验
• Safari浏览器功能增强，浏览网页更轻松

iPadOS 18将于今年秋季正式推送，届时用户可以通过OTA升级的方式获得。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.